838 related articles for article (PubMed ID: 33792454)
1. Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature.
Strzelczyk A; Grau J; Bast T; Bertsche A; Bettendorf U; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klotz KA; Kluger G; Knake S; Knuf M; Kurlemann G; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Rosenow F; Ruf S; Sauter M; Schäfer H; Schlump JU; Schubert-Bast S; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Zöllner JP
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):749-760. PubMed ID: 33792454
[TBL] [Abstract][Full Text] [Related]
2. Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries.
Słowińska M; Kotulska K; Szymańska S; Roberds SL; Fladrowski C; Jóźwiak S
Pediatr Neurol; 2021 Feb; 115():21-27. PubMed ID: 33310533
[TBL] [Abstract][Full Text] [Related]
3. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
[TBL] [Abstract][Full Text] [Related]
4. Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children.
Svarrer EMM; Fischer CM; Frederiksen MG; Born AP; Hoei-Hansen CE
Dan Med J; 2019 Dec; 66(12):. PubMed ID: 31791480
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.
Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A
CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102
[TBL] [Abstract][Full Text] [Related]
7. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.
Overwater IE; Bindels-de Heus K; Rietman AB; Ten Hoopen LW; Vergouwe Y; Moll HA; de Wit MC
Epilepsia; 2015 Aug; 56(8):1239-45. PubMed ID: 26046563
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
[TBL] [Abstract][Full Text] [Related]
9. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
11. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.
Curatolo P; Nabbout R; Lagae L; Aronica E; Ferreira JC; Feucht M; Hertzberg C; Jansen AC; Jansen F; Kotulska K; Moavero R; O'Callaghan F; Papavasiliou A; Tzadok M; Jóźwiak S
Eur J Paediatr Neurol; 2018 Sep; 22(5):738-748. PubMed ID: 29880258
[TBL] [Abstract][Full Text] [Related]
12. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
[TBL] [Abstract][Full Text] [Related]
13. Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex.
van der Poest Clement EA; Sahin M; Peters JM
J Child Neurol; 2018 Jul; 33(8):519-524. PubMed ID: 29687739
[TBL] [Abstract][Full Text] [Related]
14. Epileptic spasms in tuberous sclerosis complex.
Hsieh DT; Jennesson MM; Thiele EA
Epilepsy Res; 2013 Sep; 106(1-2):200-10. PubMed ID: 23796861
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
17. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
Aronica E; Specchio N; Luinenburg MJ; Curatolo P
Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect costs and cost-driving factors of Tuberous sclerosis complex in children, adolescents, and caregivers: a multicenter cohort study.
Grau J; Zöllner JP; Schubert-Bast S; Kurlemann G; Hertzberg C; Wiemer-Kruel A; Bast T; Bertsche A; Bettendorf U; Fiedler B; Hahn A; Hartmann H; Hornemann F; Immisch I; Jacobs J; Kieslich M; Klein KM; Klotz KA; Kluger G; Knuf M; Mayer T; Marquard K; Meyer S; Muhle H; Müller-Schlüter K; Noda AH; Ruf S; Sauter M; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wilken B; Willems LM; Rosenow F; Strzelczyk A
Orphanet J Rare Dis; 2021 Jun; 16(1):282. PubMed ID: 34154622
[TBL] [Abstract][Full Text] [Related]
19. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.
van der Poest Clement E; Jansen FE; Braun KPJ; Peters JM
Paediatr Drugs; 2020 Feb; 22(1):73-84. PubMed ID: 31912454
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature.
Zöllner JP; Grau J; Rosenow F; Sauter M; Knuf M; Kurlemann G; Mayer T; Hertzberg C; Bertsche A; Immisch I; Klein KM; Knake S; Marquard K; Meyer S; Noda AH; von Podewils F; Schäfer H; Thiels C; Willems LM; Zukunft B; Schubert-Bast S; Strzelczyk A
Orphanet J Rare Dis; 2021 Jun; 16(1):250. PubMed ID: 34078440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
